Shares of Krystal Biotech Inc (NASDAQ:KRYS) have been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $35.00.
A number of analysts have issued reports on the company. Zacks Investment Research raised Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Saturday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Krystal Biotech in a report on Monday, October 15th. William Blair assumed coverage on Krystal Biotech in a report on Monday, August 6th. They set a “buy” rating for the company. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Krystal Biotech in a report on Monday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Krystal Biotech in a report on Monday.
In other news, insider Krish S. Krishnan bought 25,000 shares of the business’s stock in a transaction dated Thursday, October 18th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 45.80% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of KRYS. Acadian Asset Management LLC increased its position in shares of Krystal Biotech by 552.2% during the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares in the last quarter. BlackRock Inc. increased its position in shares of Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares in the last quarter. Finally, P.A.W. Capital Corp acquired a new stake in shares of Krystal Biotech during the third quarter worth about $527,000. Institutional investors and hedge funds own 22.04% of the company’s stock.
NASDAQ KRYS traded down $0.63 during trading on Tuesday, reaching $21.60. 43,965 shares of the company’s stock were exchanged, compared to its average volume of 45,041. The company has a market capitalization of $248.89 million, a price-to-earnings ratio of -14.59 and a beta of -0.81. Krystal Biotech has a 1 year low of $8.03 and a 1 year high of $24.89.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.26). Equities analysts anticipate that Krystal Biotech will post -1.01 earnings per share for the current year.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Article: Initial Public Offering (IPO)
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.